Taipei Exchange - Delayed Quote TWD

NatureWise Biotech & Medicals Corporation (4732.TWO)

19.75
-0.55
(-2.71%)
At close: 2:26:16 PM GMT+8
Loading Chart for 4732.TWO
  • Previous Close 20.30
  • Open 20.25
  • Bid 18.90 x --
  • Ask 19.75 x --
  • Day's Range 19.00 - 20.25
  • 52 Week Range 17.40 - 27.50
  • Volume 72,496
  • Avg. Volume 51,350
  • Market Cap (intraday) 1.11B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 987.50
  • EPS (TTM) 0.02
  • Earnings Date --
  • Forward Dividend & Yield 0.18 (0.89%)
  • Ex-Dividend Date Aug 27, 2024
  • 1y Target Est --

NatureWise Biotech & Medicals Corporation engages in the development of therapeutic drugs in Taiwan. It offers LipoCol Forte, a capsule for hypercholesterolemia and hypertriglyceridemia; PPL Taiwan green propolis; and NBM-BMX, an oral softgel capsule to treat cancer. The company was founded in 2000 and is based in Taipei, Taiwan.

www.naturewise.com.tw

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4732.TWO

View More

Performance Overview: 4732.TWO

Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

4732.TWO
20.36%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
5.66%

1-Year Return

4732.TWO
23.60%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
2.76%

3-Year Return

4732.TWO
34.94%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
37.25%

5-Year Return

4732.TWO
9.49%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
100.93%

Compare To: 4732.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4732.TWO

View More

Valuation Measures

Annual
As of 5/14/2025
  • Market Cap

    1.11B

  • Enterprise Value

    501.72M

  • Trailing P/E

    990.00

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.96

  • Price/Book (mrq)

    1.50

  • Enterprise Value/Revenue

    2.24

  • Enterprise Value/EBITDA

    67.28

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.40%

  • Return on Assets (ttm)

    -0.98%

  • Return on Equity (ttm)

    -0.50%

  • Revenue (ttm)

    224.32M

  • Net Income Avi to Common (ttm)

    897k

  • Diluted EPS (ttm)

    0.02

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    614.73M

  • Total Debt/Equity (mrq)

    0.43%

  • Levered Free Cash Flow (ttm)

    -3.58M

Research Analysis: 4732.TWO

View More

Company Insights: 4732.TWO

Research Reports: 4732.TWO

View More

People Also Watch